Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05881213
Other study ID # A129_02BE2227
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 1, 2023
Est. completion date July 10, 2023

Study information

Verified date May 2023
Source Chong Kun Dang Pharmaceutical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-378


Description:

A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety after Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date July 10, 2023
Est. primary completion date June 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 55 Years
Eligibility Inclusion Criteria: 1. Healthy adults aged between 19 and 55 years at screening. 2. Those whose body weight 55 kg or over for men and 50 kg or over for women. 3. Those with body mass index (BMI) was more than 18.5 kg/m2 and less than 27.0 kg/m2. ? BMI (kg/m2) = body weight (kg)/ [height (m)]2 4. If women, those who met any one of the following criteria. - Menopause (no natural menstruation for at least 2 years) - Surgical infertility (hysterectomy or bilateral oophorectomy, tubal ligation, or infertility by other methods) 5. Male subjects with female sexual partners of childbearing potential must agree to use methods of birth control (using condom) and not donate sperm during the study and for up to 28 days after the last administration of the IP (unless the male subjects or their female partners are infertile). 6. Subjects who have voluntarily given written informed consent to participate in the study and comply with all study requirements after getting a detailed explanation and full understanding of the study. Exclusion Criteria: 1. Subjects with history or current conditions of clinically significant disease, including hepatobiliary (e.g., severe hepatic dysfunction, etc.), renal (e.g., severe renal insufficiency, etc.), nervous, immune, respiratory (e.g., bronchial asthma) urinary, gastrointestinal, endocrine (e.g., patients with diabetic ketoacidosis, diabetic coma and pre-coma, and type 1 diabetes mellitus, etc.), hemato-oncology, or cardiovascular (e.g., heart failure, etc.) or psychiatric disorders. 2. Subjects who are susceptible to dehydration due to inadequate oral intake or who have clinically significant dehydration. 3. Subjects who underwent a test using intravenous administration of radioiodine contrast media (e.g., intravenous urography, venous cholangiography, angiography, or computed tomography using a contrast medium) within 48 hours prior to the first IP administration. 4. Subjects with a history or current conditions of serious urinary tract infection. 5. Subjects with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. 6. Subjects with a history of gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis, etc.) or surgery (except simple appendectomy or hernia surgery) that may affect the absorption of IP. 7. Subjects with a history of clinically significant hypersensitivity to drugs, including components of the IPs (empagliflozin or metformin) or additives. 8. Subjects who were deemed unfit for participation in this study based on the following findings in the screening tests performed within 28 days before the first IP administration. - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values > 1.25 times the upper limit of normal range. - Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 when calculated with the modification of diet in renal disease (MDRD) formula. - Positive result for hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or syphilis infection test. - Systolic blood pressure > 150 mmHg or <90 mmHg, or diastolic blood pressure > 100 mmHg or <50 mmHg which is measured in sitting position after resting for more than 5 minutes. 9. Subjects with a history of drug abuse within a year prior to screening or positive results in urine drug screening tests. 10. Women who are pregnant or breast-feeding. 11. Subjects who took the following drugs, excluding the topical agents without significant systemic absorption, within the predefined period the investigator judges they could affect the results of the study or compromise the safety of the subject. - Any prescription drugs and herbal medicines within 14 days before the first IP administration. - Any over-the-counter drugs including health care foods or vitamins within 7 days before the first IP administration - Any drugs administered by depot injection or other implantation into the body within 30 days before the first IP administration 12. Subjects who took any drugs that induce or inhibit drug metabolizing enzymes, such as barbital drugs, within 30 days before the first IP administration. 13. Subjects with excessive smoking (>10 cigarette/day), caffeine intake (caffeine:>5 cups/day), or drinking (alcohol: >210 g/week) or who cannot stop from smoking, caffeine intake, and drinking during the hospitalization period. 14. Subjects who have consumed foods containing grapefruit within 7 days prior to the first IP administration or cannot stop consuming foods containing grapefruit during the study. 15. Subjects who were administered any other IPs by participating in other clinical trials within 180 days before the first IP administration (in the case of biological agent, taking account of its half-life, this period can be extended). 16. Subjects who donated whole blood within 60 days or blood components for apheresis within 30 days before the first IP administration. 17. Subjects who received blood transfusion within 30 days before the first IP administration. 18. Subjects judged by the investigators unsuitable for participating in the study based on any other reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CKD-378 (low-dose)
Quaque day (QD), PO

Locations

Country Name City State
Korea, Republic of Severance Hospital, Yonsei University College of Medicine Seoul

Sponsors (1)

Lead Sponsor Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary area under the curve (AUC)t of CKD-378 Area under the concentration-time curve time zero to time Pre-dose(0 hour) to 48 hours
Primary Cmax of CKD-378 Maximum plasma concentration of the drug Pre-dose(0 hour) to 48 hours
See also
  Status Clinical Trial Phase
Withdrawn NCT04569214 - The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients Phase 2
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Completed NCT01698528 - Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration N/A
Completed NCT00985114 - Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity N/A
Active, not recruiting NCT05120219 - A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers Phase 1
Completed NCT04893135 - Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes N/A
Not yet recruiting NCT05108350 - A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects Phase 1
Completed NCT02586129 - Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes Phase 3
Completed NCT02914743 - Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes N/A
Completed NCT04540016 - Mass Balance and Biotransformation of [14C]HSK7653 in Human Phase 1
Completed NCT02429258 - Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin Phase 4
Completed NCT01055223 - Fracture Risk With Thiazolidinediones N/A
Terminated NCT02365233 - Fatty Liver Study in Patients With Type II Diabetes Phase 4
Completed NCT05878587 - Burger Allen Exercises in Knee OA With Type II Diabetes N/A
Completed NCT04768673 - A Study to Investigate the PK and Safety of CKD-393 Phase 1
Not yet recruiting NCT05028140 - Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus Phase 3
Terminated NCT01804777 - Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes Early Phase 1
Completed NCT01619332 - Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Phase 1/Phase 2
Active, not recruiting NCT06387433 - Effectiveness of an mHealth Mobile App N/A
Completed NCT01881074 - Periodontal Treatment Response in Type II Diabetic Patients